Application of compound medicine composition in preparation of medicine for treating interstitial pneumonia

A composition and interstitial technology, applied in the field of compounds, to achieve significant curative effect advantages and obvious synergistic effects
CN114557992APending Publication Date: 2022-05-31CHINA PHARM UNIV
1 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHINA PHARM UNIV
Publication Date
2022-05-31

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an application of a compound medicine composition taking sarpogrelate and carbidopa as active ingredients in preparation of a medicine for treating interstitial pneumonia, the compound medicine composition can inhibit 5-hydroxytryptamine (5-HT) synthetase and 5-HT2A receptor (5-HT2AR) activity of lung tissue cells (including macrophages), and can inhibit the activity of sarpogrelate and carbidopa. Specifically, the 5-HT2AR antagonist sarpogrelate and the 5-HT synthetic inhibitor carbidopa form a compound within a certain weight ratio range, and the composition has an obvious synergistic effect on treatment of interstitial pneumonia and has an obvious treatment effect.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the application of a class of compounds, in particular to the application of a compound pharmaceutical composition in the preparation of drugs for treating interstitial pneumonia. Background technique

[0002] Interstitial pneumonia (IP) is caused by various factors such as radiation, chemicals (bleomycin (BLM), silica, asbestos, etc.), infection (respiratory virus, bacteria, etc.), etc. Inflammatory and fibrotic lesions of the lungs. The etiology that can cause IP is very wide. According to the etiology, it is divided into rheumatic immune diseases of known etiology, drug or treatment-related diseases (antiarrhythmic drugs, chemotherapy drugs, paraquat, sulfasalazine, radiotherapy, etc.), occupational and environmental diseases (silicosis, asbestosis, coal pneumoconiosis, etc.), and primary diseases of unknown etiology (sarcoidosis, lymphangiomuscular neoplastic disease, eosinophilic pneumonia, etc.) or idiopathic di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More